Meeting
2011 ASCO Annual Meeting
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.
Authors
M. M. Javle
University of Texas M. D. Anderson Cancer Center, Houston, TX
M. M. Javle , G. R. Varadhachary , D. R. Fogelman , R. T. Shroff , M. J. Overman , L. Ukegbu , B. N. Bekele , S. P. Kar , R. A. Wolff , J. L. Abbruzzese
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4026)
Abstract #
4026
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).
First Author: Dirk Strumberg
Poster
2017 Gastrointestinal Cancers Symposium
A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
First Author: Boram Han
Poster
2013 Gastrointestinal Cancers Symposium
Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.
First Author: Katherine Fan
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery